We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NBTX:NASDAQNanobiotix S.A. analysis

Data as of Oct 14, 2026 - not real-time

Latest price
$21.49
Risk: high
9/10High risk

Summary

Nanobiotix S.A. trades at $21.49, with its moving averages tangled rather than clearly stacked — a neutral trend structure. Over a rolling month the price has lost 47.1%. Relative strength is 21.8 — oversold — and the MACD signal is bearish. Watch $21.22 as support and $36.10 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 150.4% above today's level. Revenue is contracting at 79.2%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 64.2%, a beta of 1.66 and a maximum drawdown of 61.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.

Top market events

  • PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 GLOBE NEWSWIRE -- NANOBIOTIX Euronext: NANO - NASDAQ: NBTX - the...
  • Nanobiotix S.A. NASDAQ:NBTX reported September 14 results from all 24 patients in the dose-escalation and expansion...
  • Nanobiotix, a late-stage clinical biotech company, named Arnd Christ as CFO effective October 1, 2026.

Market outlook

Short term

< 1 year

Neutral

Model confidence1/101 out of 10

Key factors

  • RSI at 21.8 signals oversold conditions
  • Trading below the 200-day average of 33.44
  • MACD momentum is negative

Medium term

1–3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • RSI at 21.8 signals oversold conditions
  • Trading below the 200-day average of 33.44
  • Analyst targets imply +150.4% versus the current price

Long term

> 3 years

Neutral

Model confidence1/101 out of 10

Key factors

  • Analyst targets imply +150.4% versus the current price
  • Revenue contracting at -79.2%
  • Negative free cash flow

Key metrics

Financial health

Revenue Growth-79.20%
P/E Ratio-129.0
ROA-21.34%
P/B Ratio-29.3
Op. Cash Flow$-34186000
Free Cash Flow$-32782250
Industry P/E30.3

Technical analysis

TrendNeutral
RSI21.8
Support$21.22
Resistance$36.10
MA 20$29.52
MA 50$35.70
MA 200$33.44
MACDBearish
VolumeIncreasing
Fear & Greed Index94.2

Valuation

Target Price$53.81
Upside/Downside150.40%
GradeFair
TypeBlend

Risk assessment

Beta1.66
Volatility64.21%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.